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Essays on information asymmetry,  
disclosures and the financing of R&D 
The case of the biotechnology industry 
Investments in research and development (R&D) are an important driver of innovation, 
productivity and economic growth. Despite the importance of R&D investments to society, it is 
commonly known that R&D activities are difficult to finance in a competitive marketplace. 
Corporate investments in intangible assets, such as R&D, create information asymmetry 
problems between corporate insiders and outsiders. Several additional factors contribute to 
information asymmetry: the relative uniqueness of R&D to the developing firm, the lack of 
organized markets for trading R&D assets and the scarcity of R&D information in corporate 
reports. As a result, Hall and Lerner (2009) suggest that the marketplace for financing R&D 
looks like the “lemons” market (Akerlof, 1970). 
This thesis studies asymmetric information in the context of two major corporate events in the 
biotechnology industry: corporate financing of R&D and corporate takeovers. The two essays 
on corporate financing of R&D examine how biotech firm managers access capital markets to 
raise external financing to finance capital-intensive R&D investments and how they choose 
between alternative equity flotation methods. The essay on corporate takeovers investigates the 
role of asymmetric information in corporate takeovers between acquiring and target firms and 
the subsequent performance of R&D. 
The results of this thesis indicate that corporate managers issue equity to a larger extent 
following the disclosure of R&D information, i.e. when the degree of asymmetric information 
is low, and when the stock is temporarily mispriced. Biotech stocks generate positive abnormal 
returns in the period prior to the equity issue announcement and negative abnormal returns in 
the period thereafter. The results also indicate that the degree of asymmetric information plays 
a role in the choice of equity-selling mechanisms. Biotechnology firms issue equity publicly 
rather than privately following disclosures of R&D information. Finally, the empirical results 
show that R&D projects that are co-developed prior to the acquisition are no more likely to 
advance to subsequent stages of development than are R&D projects that are not preceded by 
alliances, which raises questions regarding the ability of R&D alliances to serve as a mechanism 
to mitigate information asymmetry problems. 
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